Drug Profile
Lamotrigine intravenous - CyDex
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator CyDex Pharmaceuticals
- Class Antidepressants; Antiepileptic drugs; Chlorobenzenes; Mood stabilisers; Small molecules; Triazines
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seizures
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Seizures in USA (IV, Injection)
- 05 Feb 2020 Preclinical trials are underway for Seizures in USA (Ligand Pharmaceuticals pipeline, February 2020)
- 10 Sep 2014 Ligand Pharmaceuticals out-licenses CE-lamotrigine to CURx Pharmaceuticals